Program
SL1002
A development code. Also written as “SL-1002”.
Its studies are mostly in Osteoarthritis, Knee · Muscle Spasticity · Osteoarthritis, led by Saol Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Saol Therapeutics | 33 open or running | phase 3since Nov 6, 2025 | Mar 28, 2022 | Nov 30, 2026phase 3 · NCT07226258 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 28, 2022First study: phase 2 study in Muscle SpasticityFirst studyNCT05311215 · 32 enrolled · United States
- Jul 20, 2022Phase 2 study in OsteoarthritisNCT05470608 · 132 enrolled · United States
- Nov 6, 2025Phase 3 study in Osteoarthritis Knee PainNCT07226258 · 150 enrolled · United States
Ahead
- Nov 30, 2026Primary completion: phase 3 study in Osteoarthritis Knee PainNCT07226258
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07226258Osteoarthritis Knee Pain · United States | 3 | Active, not recruiting | Nov 30, 2026 | 150 |
| NCT05470608Osteoarthritis · United States | 2 | Active, not recruiting | Jan 2024 | 132 |
| NCT05311215Muscle Spasticity · United States | 2 | Active, not recruiting | Sep 2023 | 32 |
How it is read
Names in the registry
- “SL-1002”, 2 entries
- “SL1002”, 1 entry
Codes read as this program: SL1002.
Conditions, from the studies’ own filings
- Osteoarthritis, Knee, 1 study
- Muscle Spasticity, 1 study
- Osteoarthritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.